COPD

HCPLive convened an in-depth roundtable discussion on advancing biologic therapy for asthma and COPD in a complex real-world prescribing environment.

May 2026 spotlights the ATS 2026 conference and the ALA's State of the Air report.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.

At ATS 2026, investigators reported that pediatric pulmonary rehabilitation improved exercise capacity and quality of life in chronic respiratory disease.

Clinicians at ATS 2026 will see late-breaking COPD, asthma, and pulmonary hypertension data alongside exclusive interviews with leading experts in respiratory medicine.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

The Q1 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

March 2026 saw new data from pivotal clinical trials and new expert conversations on HCPLive.

Deep learning applied to routine ECGs identifies subtle cardiac signals linked to early COPD, potentially enabling earlier diagnosis and intervention.

Deep learning applied to routine ECGs identified COPD up to 15 months earlier, supporting earlier intervention and risk stratification strategies.

AstraZeneca's investigational IL-33–targeting antibody tozorakimab met its primary endpoint in both the phase III OBERON and TITANIA trials.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

At AAAAI 2026, Ramsey discussed the shift toward race-neutral spirometry equations, their clinical implications, and barriers to widespread adoption.

New biologics transform severe asthma and COPD, yet prednisone overuse persists—see practical selection tips and outpatient steroid stewardship gaps.

Experts weigh new biologics including dupilumab, tezepelumab, and depemokimab, and how eosinophils guide real-world prescribing.

February 2026 saw new data and expert interviews from AAAAI 2026.

Using race-neutral spirometry equations such as GLI 2012 and GLI 2022 may improve diagnostic accuracy and reduce disparities in lung disease assessment.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.

A clinical forum focuses on how advanced practice providers (APP) and clinicians are now navigating how to translate emerging data into real-world practice.